The CRH-binding protein (CRH-BP) antagonizes the ACTH-releasing activity of the neuropeptide CRH in vitro. However, the function of CRH-BP in vivo and the molecular mechanisms that regulate CRH-BP expression are not well understood. In this study, the rat CRH-BP gene was characterized, and CRH-BP promoter sequences were identified. The rat CRH-BP gene spans almost 12 kilobases and contains 7 exons. Ribonuclease protection experiments indicate that transcription of the CRH-BP gene initiates at multiple sites in rat cerebral cortex. Transfection experiments with CRH-BP-reporter constructs, containing 88 -3500 bp 5Ј flanking and 66 bp 5Ј untranslated DNA from the rat CRH-BP gene, demonstrate basal promoter activity in multiple cell lines. CRH-BP-reporter constructs also demonstrate positive regulation of promoter activity by cAMP in a variety of cell lines and by CRH in cells expressing the CRH receptor. The DNA sequences between Ϫ341 and Ϫ88 bp, including the cAMP response element-like sequence at Ϫ127 bp, are required for maximal cAMP and CRH regulation of CRH-BP promoter activity. These studies suggest that CRH-BP transcription in vivo may be positively regulated by cAMP and CRH. (Endocrinology
constructs, containing 88 -3500 bp 5Ј flanking and 66 bp 5Ј untranslated DNA from the rat CRH-BP gene, demonstrate basal promoter activity in multiple cell lines. CRH-BP-reporter constructs also demonstrate positive regulation of promoter activity by cAMP in a variety of cell lines and by CRH in cells expressing the CRH receptor. The DNA sequences between Ϫ341 and Ϫ88 bp, including the cAMP response element-like sequence at Ϫ127 bp, are required for maximal cAMP and CRH regulation of CRH-BP promoter activity. These studies suggest that CRH-BP transcription in vivo may be positively regulated by cAMP and CRH. (Endocrinology 138: 2098 -2108, 1997) C RH IS A 41-amino acid neuroendocrine peptide that regulates a variety of physiological responses to stress. CRH mediates its effects via specific, G protein-coupled CRH receptors that are expressed in numerous regions of the brain and in several peripheral sites, including anterior pituitary. Within the hypothalamic-pituitary-adrenal axis, CRH is the primary hypothalamic regulator of ACTH secretion from anterior pituitary corticotrophs. In the brain, CRH is thought to act as a neurotransmitter/neuromodulator, coordinating a variety of autonomic and behavioral responses to stress (1) . In the periphery, CRH also may be involved in immune/ inflammatory responses (2, 3) and developmental processes (4, 5) .
The CRH-binding protein (CRH-BP) is a 37-kDa secreted glycoprotein that binds human CRH with an affinity greater than the pituitary CRH receptor [K i ϭ 0.4 and 1.7 nm, respectively (6 -9) ]. This binding protein blocks the ACTHreleasing activity of CRH in vitro on rat anterior pituitary primary cultures and mouse anterior pituitary tumor (AtT-20) cells (7, 8, 10) . In situ hybridization and immunocytochemical analyses have demonstrated that the CRH-BP is expressed in rat brain and anterior pituitary corticotrophs (11) . In the brain, CRH-BP is expressed predominantly in the cerebral cortex and subcortical limbic structures and colocalizes with CRH or CRH receptors in several brain regions (11, 12) . The overlapping patterns of CRH-BP, CRH, and CRH receptor expression in brain and pituitary suggest that the CRH-BP may alter the in vivo interaction of CRH with the CRH receptor, thus modulating the activity of CRH. The CRH-BP also may play a role in regulating the activity of the novel, CRH-like peptide, urocortin, which also binds to the CRH-BP with high affinity [K i ϭ 0.1 nm (13) ].
Although the in vivo distribution of CRH-BP mRNA expression and the in vitro interaction of CRH and CRH-BP have been characterized, the exact physiological role of the CRH-BP has not been determined. In the brain, 40 -60% of CRH peptide is bound to the CRH-BP (14, 15) , consistent with studies suggesting that CRH-BP can modulate the effects of CRH on behavior (16 -18) . However, in humans, CRH-BP mRNA is expressed not only in brain, but also in liver and placenta (7, 19) , where it may regulate CRH activity during pregnancy (10, 20, 21) .
Although these results suggest that CRH-BP may act as a carrier and/or modulator of CRH, little is known about the molecular mechanisms regulating CRH-BP mRNA expression. Studies in primary astrocyte cultures, showing increased CRH-BP steady-state mRNA levels after forskolin/ isobutylmethylxanthine (IBMX) treatment, provide our only insight into the regulation of CRH-BP mRNA expression in mammalian brain (22) . Because aberrant CRH activity is associated with several psychiatric and neurological disorders, including major depression and Alzheimer's disease, an understanding of the mechanisms that regulate CRH-BP gene expression in the brain and pituitary may have important clinical implications (1, 14) .
To further define the molecular mechanisms regulating CRH-BP gene expression, we have characterized the rat CRH-BP gene structure and mapped the CRH-BP transcrip-tion initiation sites in rat brain by ribonuclease (RNase) protection assays. Transfection experiments with CRH-BP reporter constructs have been used to identify functional CRH-BP promoter sequences and to demonstrate positive regulation of CRH-BP promoter activity by cAMP and CRH.
Materials and Methods

Complementary DNA (cDNA) cloning
The rat CRH-BP cDNA sequence published by Potter and colleagues (7) contained nucleotide sequence corresponding to the 5Ј untranslated and protein coding regions of the rat CRH-BP cDNA. To obtain the nucleotide sequence of the 3Ј untranslated region, a rat CRH-BP cDNA was isolated from a rat brain cDNA library (courtesy of Dr. G. X. Xie, University of Michigan). The library was screened in duplicate using a 666-bp PvuII fragment of the rat CRH-BP cDNA isolated by RT-PCR from rat pituitary RNA (8) . Filters were hybridized for 20 h at 37 C in Hybridization Buffer (5ϫ sodium chloride/sodium citrate (SSC), 25 mm sodium phosphate (pH 6.5), 5ϫ Denhardts, 5 mm EDTA, 0.1% SDS, and 0.1% sodium pyrophosphate) containing 50% formamide, 100 g/ml yeast RNA, and 1 ϫ 10 6 cpm of denatured probe per milliliter of buffer. The filters were washed twice in 2ϫ SSC, 0.1% SDS, 0.1% sodium pyrophosphate for 15 min at room temperature followed by a 30-min wash in 0.2ϫ SSC, 0.1% SDS, 0.1% sodium pyrophosphate at 50 C. The filters were exposed to Kodak XAR-5 film (Eastman Kodak, Rochester, NY) for 16 h at Ϫ80 C with intensifying screens. Three hybridizationpositive clones were identified and characterized by Southern blot analysis. The entire nucleotide sequence of the clone containing the largest cDNA insert, 7A1, was obtained using Sequenase Version 2.0 (Amersham Life Sciences, Arlington Heights, IL) and deoxy GTP mixes, as described by the manufacturer. The University of Wisconsin Genetics Computer Group (Madison, WI) Sequence Analysis Software Package (GAP program) was used for nucleotide sequence homology determinations.
Isolation of genomic clones
An EMBL-3 Sp6/T7 Sprague Dawley rat genomic library (Clontech, Palo Alto, CA) was plated on Escherichia coli NM538 and screened in duplicate with the previously described 666-bp PvuII fragment of the rat CRH-BP cDNA (8) . Hybridization conditions were as described above. Two hybridization-positive plaques were plaque-purified. The rat CRH-BP genomic clones were mapped by restriction endonuclease and Southern blot analyses using the 666-bp PvuII fragment and numerous rat CRH-BP cDNA-specific oligonucleotides as hybridization probes. DNA fragments were subcloned and nucleotide sequencing performed on both strands, as described above. Nucleotide sequences were numbered using the human liver CRH-BP transcription initiation site as ϩ1 (23) .
Southern blot analysis
Ten micrograms of Sprague-Dawley rat genomic DNA were digested with 20 U of restriction endonuclease (PvuII, PstI, or SacI). The reactions were electrophoresed with DNA size standards (1 kilobase (kb) DNA ladder, Life Technologies, Gaithersburg, MD) on a 0.8% agarose gel and then transferred to a Nytran membrane (Schleicher and Schuell, Keene, NH). Hybridization was performed at 55 C in Hybridization Buffer (see above) containing 100 g/ml yeast RNA and 1 ϫ 10 6 cpm of denatured probe per ml buffer. One blot was hybridized with the random-primed 666-bp PvuII fragment of the rat CRH-BP cDNA clone, spanning exons 3-7. A second genomic Southern blot was hybridized with a randomprimed 187-bp SphI/PstI fragment of the rat CRH-BP cDNA clone (exon 7). The blots were washed successively in 2ϫ SSC, 0.1% SDS at room temperature for 15 min and 0.1ϫ SSC, 0.1% SDS, and 0.1% sodium pyrophosphate for 30 min at 60 C. The blots were exposed to film for 48 -72 h at Ϫ80 C with intensifying screens. Because of incomplete digestion of the genomic DNA with the restriction enzymes, weakly hybridizing bands are observed at high molecular weights in some of the lanes.
RNase protection assays
Total RNA was isolated from rat cerebral cortex, pituitary, and liver by standard methods (24, 25 32 P-UTP (Ͼ3000 Ci/mmol, ICN Pharmaceuticals), 1 l RNasin (28 U/l, Promega), 10 mm DTT, 0.5 mm each of ATP, GTP, and CTP, 10 m UTP in 1ϫ transcription buffer (Epicentre) in a vol of 20 l. The reaction was incubated at 41 C for 90 min. One unit of RNase-free DNase I (Promega) was added, and the reaction was incubated for 10 min at room temperature. To terminate the reaction, 20 l Loading Dye (95% formamide, 1 mm EDTA, 0.1% xylene cyanol, 0.1% bromophenol blue) were added, followed by a 5-min incubation at 70 C. This sample was then electrophoresed on a 6% polyacrylamide/7 m urea gel. Full-length probe was excised from the gel and eluted in 300 l 0.5 m ammonium acetate, 1 mm EDTA, 0.2% SDS. For solution hybridization, 50 g total RNA were precipitated with 0.5-1.0 ϫ 10 6 cpm cRNA probe, and the pellet was resuspended in 30 l Solution A [80% deionized formamide, 100 mm sodium citrate (pH 6.4), 300 mm sodium acetate (pH 6.4), 1 mm EDTA; Ambion, Inc., Madison, WI]. The samples were incubated at 95 C for 5 min and then immediately immersed in a 60 C water bath for 12-20 h. Samples were allowed to cool to room temperature for 5-10 min, and 200 l Solution Bx (Ambion, Inc.) containing 5 g/ml RNase A and 100 U/ml RNase T1 were added to each tube. Samples were incubated 60 min at 37 C. Subsequently, 300 l Solution Dx (Ambion) and 200 l 100% ethanol were added to terminate the reaction and precipitate RNA hybrids. RNA pellets were resuspended in Loading Dye and analyzed on 6% polyacrylamide/7 m urea gels. Radiolabeled RNA probes of various sizes and DNA sequencing reactions were used as size standards. Dried gels were exposed to XAR film for various lengths of time.
Cell culture and transfection experiments
AtT-20 (mouse anterior pituitary corticotrope), COS-1 (monkey kidney), NIE-115 (mouse neuroblastoma), and Neuro-2a (mouse neuroblastoma) cells were maintained in DMEM (Life Technologies) containing 10% heat-inactivated FCS (Hyclone, Logan, UT) at 37 C and 5% CO 2 . PC12 (rat adrenal pheochromocytomoma) cells were maintained in DMEM supplemented with 10% heat-inactivated horse serum and 5% FCS. ␣TSH (mouse anterior pituitary thyrotrope) cells were provided by Dr. Pamela L. Mellon (University of California, San Diego, CA) and were maintained as described previously (26) .
The 3500-bp SacI fragment of the rat CRH-BP gene was subcloned into the PXP2 luciferase reporter plasmid (27) in both orientations to give clones 3500BP-LUC and 3500BPrev-LUC. The 407-bp NdeI/SacI fragment (nucleotides Ϫ341 to ϩ66) of the rat CRH-BP gene was independently subcloned into PXP2 to create the plasmid 341BP-LUC. Other CRH-BP-LUC reporter constructs were derived from the 3500BP-LUC construct by restriction endonuclease digestion with BamHI or NcoI to form the 631BP-LUC (Ϫ631 to ϩ66) or the 88BP-LUC (Ϫ88 to ϩ66) plasmids, respectively. Six-centimeter plates containing approximately 250,000 cells (␣TSH, COS-1, NIE-115, Neuro-2a) or 500,000 cells (AtT-20, PC12) were transfected with 12.5 g reporter DNA using the calcium phosphate method, as previously described (28) . A CMV␤-galactosidase expression vector (CMV␤gal; a gift of Dr. Michael Uhler, University of Michigan) was included in these transfections for normalization purposes. Forty-eight hours post transfection, cells were washed and harvested in PBS. Cell pellets were lysed in 135-200 l 0.25 m Tris (pH 8.0), 0.1 mm EDTA, 15 mm magnesium sulfate, 1% Triton X-100 and incubated on ice for 10 min. Cell membranes and other debris were removed by centrifugation at 10,000 ϫ g for 10 min at 4 C. Luciferase activity was determined by combining 5-50 l extract with 100 l luciferase assay buffer (20 mm Tris (pH 8.0), 1.07 mm magnesium carbonate, 2.67 mm magnesium sulfate, 0.1 mm EDTA, 33.3 mm DTT, 0.27 mm Coenzyme A (Calbiochem, San Diego, CA), 0.53 mm ATP, and 0.47 mm luciferin (Analytical Luminescence, Ann Arbor, MI) in a LKB luminometer and assaying for 30 sec. ␤-galactosidase activity was assayed as previously described (29) . Luciferase activity was normalized to ␤-galactosidase activity to control for differences in transfection efficiency.
For regulation studies, the 3500-bp SacI, the 407-bp NdeI/SacI (containing nucleotides Ϫ341 to ϩ66), and the 154-bp NcoI/SacI (containing nucleotides Ϫ88 to ϩ66) fragments of the rat CRH-BP gene were subcloned into the promoterless chloramphenicol acetyltransferase (CAT) reporter plasmid, pGSVOCAT (30) , to produce the 3500BP-CAT, 341BP-CAT, and 88BP-CAT constructs, respectively. PCR was used for sitedirected mutagensis to create the 341(⌬CRE)BP-CAT construct using 341BP-CAT as template and the following primers: T7 primer (5ЈTA-ATACGACTCACTATAGGG3Ј; anneals to plasmid sequences), BPCREmut1 (5ЈTGGACCCTCTCGATCGCCACG3Ј; from Ϫ135 to Ϫ115 bp), BPCREmut2 (5Ј CGTGGCGATCGAGAGGGTCCA 3Ј), and a CAT primer (5ЈCTTTACGATGCCATTGGG3Ј). The mutated nucleotides are underlined. The overlapping DNA fragments resulting from PCR with BPCREmut1/CAT and BPCREmut2/T7 primer pairs were combined and subjected to a second round of PCR with the T7 and CAT primers to amplify the sequences from Ϫ341 to ϩ66 bp, including the CRE mutation. This PCR product was ligated into the pGSVOCAT construct to create 341(⌬CRE)BP-CAT, and the entire PCR-derived insert was sequenced to verify the mutation and to ensure that no additional modifications were introduced. Luciferase constructs were not used for this study because the promoterless PXP2 plasmid is positively regulated by forskolin (2-fold) in many of the cell lines used (D. N. Cortright, unpublished observations). Cells were transfected, as described above, with 8 -12.5 g of each CRH-BP-CAT construct. In some experiments, cells were treated with 10 m forskolin (Calbiochem) and 250 m IBMX (Sigma) for 6 or 24 h before harvest. In other experiments, cells were treated with 10 m forskolin or 20 nm ovine CRH (oCRH; American Peptide Company, Sunnyvale, CA) for 12 or 24 h before harvest.
To examine regulation of promoter activity by CRH in cell lines that do not express endogenous CRH receptors, a mouse CRH receptor I (CRH-R1) expression vector was created. A mouse brain cDNA library was screened using a radiolabeled PCR fragment containing nucleotides 638-1025 of the mouse CRH receptor I [(31); GenBank accession no. X72305]. A partial cDNA was isolated, sequenced, and found to span nucleotides 408-2273 of mouse CRH-R1. The remaining 5Ј sequences of the mouse CRH-R1 cDNA were obtained by PCR from reverse-transcribed mouse brain cDNA. The resulting PCR fragment was ligated to the partial CRH-R1 cDNA clone to form a CRH-R1 cDNA fragment spanning nucleotides 17-2273 (31) , including the entire protein coding region. This cDNA subsequently was subcloned into the plasmid pCMVneo (8) to form CMV.CRH-R1, which expresses CRH-R1 under the control of the CMV promoter. Cells were cotransfected with 1.5 g CMV.CRH-R1 and 8 -12.5 g CRH-BP constructs and treated as previously described.
Because of low transfection efficiency with the calcium phosphate method, AtT-20 cells were transfected with CRH-BP-CAT constructs using lipofectamine (Life Technologies) according to manufacturer's specifications. Briefly, cells were cultured in 6-well plates and grown to 50% confluency. Cells were serum-deprived for 20 h before transfection. Two to 4 g DNA per well were transfected for 5 h. Cells were then grown in serum-containing media, with the addition of CRH for 15 h before harvest.
Cells were harvested 44 -48 h post transfection and lysed in 60 -100 l 250 mm Tris (pH 8.0), 0.5% Triton X-100. CAT activity was determined, as previously described (28), using 5-60 l extract for 3-22 h. The protein concentration of the cell extracts did not vary significantly.
Results
Structural organization of the rat CRH-BP gene
Approximately 1 ϫ 10 6 phage from a rat genomic library were plated and screened with the 666-bp PvuII fragment of the rat CRH-BP cDNA, as described in Materials and Methods. After secondary screens, two independent clones (3-3 and 3-4) were plaque-purified. Southern blot analysis with rat CRH-BP cDNA-specific oligonucleotide probes was used to identify and clone DNA fragments from each genomic clone that contained the exons of the rat CRH-BP gene. Nucleotide sequencing and Southern blot analysis of these clones confirmed that genomic clones 3-3 and 3-4 contained distinct, yet overlapping, DNA sequences. The rat CRH-BP gene spans almost 12 kb and contains 7 exons and 6 introns (Fig.  1, A and B) . Exon 7 is the largest exon (716 nucleotides) in the gene, including the 3Ј end of the protein coding sequence and the entire 3Ј untranslated region. The 3Ј boundary of Exon 7 was determined by comparison of the genomic sequence with rat CRH-BP cDNA clone 7A1 (see Materials and Methods) nucleotide sequences. The 3Ј untranslated DNA contains two poly(A) signal sequences (Fig. 1, underlined) and a poly(ATA) repeat (ϩ1378). Exon 1 contains the translation initiation site (ATG) and 81 bp protein coding sequence.
This gene structure is similar to the human CRH-BP gene (23) . All of the exon/intron boundaries are the same in the rat and human genes, and the sequences of the splice sites are highly conserved. The nucleotide sequences of exons 1-6 are highly homologous between the rat and human genes (78 -90% sequence identity). Exon 7 has the lowest degree of homology (61%) between the rat and human genes, largely because of the divergence of the 3Ј untranslated sequence.
Southern analysis of rat genomic DNA
Genomic Southern blot analysis was performed to verify the integrity of the rat CRH-BP genomic clones and determine the number of CRH-BP genes present in the rat genome. Rat genomic DNA was digested with a number of restriction endonucleases and analyzed by Southern blot, as described in Materials and Methods. Analysis of the genomic DNA blot with a CRH-BP cDNA hybridization probe spanning exons 3-7 (666-bp PvuII fragment, as indicated in Fig. 1A ) demonstrates multiple, hybridization-positive bands ( Fig. 2A) . However, the Exon 7-specific probe (187-bp SphI/PstI fragment of the rat CRH-BP cDNA; Fig. 1A ) hybridizes with unique SacI (9.0 kb), PvuII (900 bp), and PstI (1.0 kb) DNA fragments (Fig. 2B) , suggesting the presence of a single rat CRH-BP gene.
The sizes of the hybridization-positive fragments from genomic Southern analysis in Fig. 2 match the restriction endonuclease analysis of genomic clones 3-3 and 3-4 (Fig.  1A) , verifying the integrity of the overlapping genomic clones. For example, the 666-bp CRH-BP cDNA probe hybridizes to the 9.0-kb, 2.8-kb, and 1.4-kb SacI genomic fragments whereas the 187-bp probe recognizes only the 9.0-kb fragment. Similarly, the 666-bp hybridization probe recognizes the 5.5-kb and 3.5-kb PvuII fragments, whereas the 187-bp probe hybridizes to the 900-bp PvuII fragment containing most of exon 7.
Homology of the 5Ј flanking DNA of the rat and human CRH-BP genes
Comparison of the 5Ј flanking and 5Ј untranslated DNA sequences of the rat and human (23) CRH-BP genes indicates high sequence identity (85%) between the two genes from nucleotides ϩ77 to Ϫ215 (Fig. 3) . Promoter sequence analysis reveals multiple potential transcription factorbinding sites present in both the rat and human 5Ј flanking DNAs, based on homology to consensus binding sites. These potential transcription factor-binding sites include a CREB/ATF site [Ϫ127 to Ϫ123; (32)], a LF-A1 site [Ϫ135 to Ϫ130; (23)], one OTX site [Ϫ93 to Ϫ88; (33)], one AP-2 site [Ϫ121 to Ϫ114; (34)], two Sp1 sites (Ϫ147 to Ϫ139 and Ϫ169 to Ϫ162), and two AP-1 sites[(Ϫ177 to Ϫ171, Ϫ196 to Ϫ190 (35)]. Other potential binding sites found in the rat CRH-BP gene sequence include two TATA sites (Ϫ221 to Ϫ217 and Ϫ478 to Ϫ474), a Pit-1 site (Ϫ297 to Ϫ290), a NF-kB site (Ϫ550 to Ϫ541), an AP-1 site (Ϫ238 to Ϫ232), and an AP-2 site [Ϫ188 to Ϫ182 (35) ]. The human CRH-BP gene sequence 5Ј to nucleotide Ϫ215 contains several regions of homology (including two TATA sequences) with the rat gene sequence; however, the spacing of these regions in the 5Ј flanking DNA is different in the two genes.
Mapping of transcription initiation sites in the rat CRH-BP gene
RNase protection assays were used to determine the transcription initiation site(s) of the rat CRH-BP gene. As shown in Fig. 4A , cRNA probes corresponding to nucleotides Ϫ341 to ϩ77 or Ϫ341 to ϩ66 protect a major RNA transcript in RNA from rat cerebral cortex (lanes 2 and 4), but not yeast (lanes 3 and 5) , that is located 77 or 65 nucleotides 5Ј to the PstI and SacI sites, respectively, in the rat CRH-BP promoter (asterisk at ϩ1; Fig. 3 ). This site corresponds to the transcription initiation site of CRH-BP in human liver (23) and is located 32 bp 3Ј to a consensus TATA sequence (Ϫ31 to Ϫ25). However, longer exposures reveal additional upstream initiation sites. As shown by the representative experiment in Fig. 4B , multiple CRH-BP transcripts are present in rat cerebral cortex (lanes 2 and 5) but not in rat liver (lane 3) or yeast (lane 4) RNA. Similarly sized transcripts were protected with both the Ϫ341 to ϩ77 and Ϫ341 to ϩ66 probes, allowing for the 11-nucleotide difference in probe length. These experiments demonstrate that CRH-BP transcription initiates at multiple sites up to, but not past, nucleotide Ϫ341. The majority of transcripts initiate between size markers 77 and 160 (nucleotides Ϫ83 to ϩ1; Fig. 3 ) with greater than 50% of the transcripts initiating at ϩ1. Several of the upstream transcription initiation sites correspond to the 5Ј ends of CRH-BP cDNAs cloned from mouse brain (A. Nicoletti, unpublished observations) and the 5Ј end of the rat brain CRH-BP cDNA cloned by Potter and colleagues (7)(size marker 105, Fig. 4B and nucleotide Ϫ27, Fig. 3 ). Additional studies demonstrated a similar pattern of protected CRH-BP transcripts in pituitary RNA (data not shown).
The identification of functional CRH-BP promoter sequences
The identification of transcription initiation sites within nucleotides Ϫ341 to ϩ1 of the rat CRH-BP gene suggested that the 3.5-kb SacI fragment of the rat CRH-BP gene contained functional promoter sequences. Transfection experiments with CRH-BP-luciferase reporter constructs were used to determine the basal promoter activity within this fragment. The 3.5-kb SacI fragment was cloned into the promoterless luciferase vector [PXP2; (27) ] in two orientations. The 3500BP-LUC construct contains the fragment in the 5Ј-3Ј orientation, whereas the 3500BPrev-LUC construct contains the fragment in the opposite orientation. As shown in Fig. 5A , significant luciferase activity (relative to the promoterless PXP2 vector) was detected after transient transfection with the 3500BP-LUC construct in Neuro-2a and NIE-115 (mouse neuroblastoma), ␣TSH, AtT-20 (anterior pituitary corticotrope), PC12, and COS-1 cells. In contrast, the 3500BPrev-LUC construct lacks promoter activity in these cells, consistent with the orientation dependence of basal promoter elements.
To further examine the nucleotide sequences that mediate CRH-BP basal promoter activity, several 5Ј deletions of the 3500BP-LUC construct were tested. The construct 631BP-LUC contains nucleotides Ϫ631 to ϩ66, 341BP-LUC contains nucleotides Ϫ341 to ϩ66, and 88BP-LUC contains nucleotides Ϫ88 to ϩ66 of the rat CRH-BP gene fused to the luciferase cDNA (Fig. 5B) . COS-1, Neuro-2a, and ␣TSH cells were transiently transfected with these constructs, as well as the 3500BP-Luc and PXP2 constructs. The results, shown in Fig.  5B , demonstrate that all constructs exhibit promoter activity in the cell lines tested, indicating that as little as 88 bp rat CRH-BP 5Ј flanking DNA is required to observe basal promoter activity.
Rat CRH-BP promoter activity is induced by cAMP and CRH
The identification of potential CREB/ATF and AP-2 binding sites in the rat CRH-BP promoter sequence suggested that promoter activity might be transcriptionally regulated by cAMP. As shown in Fig. 6A , COS-1 cells transfected with the 3500BP-CAT construct, containing 3500 bp rat CRH-BP 5Ј flanking DNA, and treated with forskolin/IBMX (For/I) for 6 or 24 h demonstrate 3.6 Ϯ 0.7-fold (mean Ϯ sem) and 9.5 Ϯ 1.3-fold inductions in promoter activity, respectively. Positive cAMP regulation of the 3500BP-CAT construct also was observed in other cell lines with Neuro-2a cells demonstrating the lowest induction (2-fold relative to control) and ␣TSH cells showing the highest induction with forskolin/IBMX. Differences in the levels of phosphodiesterases, adenylate cyclases, cAMP-dependent protein kinases, and transcription factors expressed in various cell lines may partly explain these different levels of cAMP-induced promoter activity.
Because CRH receptors are positively coupled to adenylate cyclase, the positive regulation of CRH-BP promoter activity by cyclic AMP suggested that CRH might affect CRH-BP transcription. To assay for CRH regulation of CRH-BP promoter activity, ␣TSH cells were transiently cotransfected with the 3500BP-CAT and CRH receptor expression (CMV-CRH-R1) constructs. Alternatively, cells were cotransfected with the 3500BP-CAT and CMVneo constructs as a negative control. As shown in Fig. 6B , a 12-h treatment of transfected ␣TSH cells with 10 m forskolin (For) results in an 8-fold induction in CAT activity relative to control in the absence or presence of the CRH receptor. In contrast, a 12-h treatment of transfected ␣TSH cells with 20 nm oCRH results in increased activity of the 3500BP-CAT construct, relative to control levels, but only when the CRH receptor is coexpressed. These results demonstrate that CRH increases CRH-BP promoter activity in ␣TSH cells and that the increase is CRH receptor-dependent.
CRH regulation of CRH-BP promoter activity is also observed in AtT-20 cells that express endogenous CRH recep- 
Localization of 5Ј CRH-BP DNA sequences involved in cAMP and CRH regulation
To further define the nucleotide sequences in the CRH-BP 5Ј flanking region required for cAMP or CRH induction of this gene, two additional CRH-BP-CAT plasmids were constructed that contained either 341 (341BP-CAT) or 88 (88BP-CAT) bp 5Ј flanking DNA in addition to 66 bp 5Ј untranslated CRH-BP sequences. These plasmids were transfected into COS-1 and ␣TSH cells (cotransfected with CMV-CRH-R1), and CAT activity was determined after 24 h of treatment with For/I, For, or CRH. As shown in Fig. 7 , cells transfected with the 341BP-CAT construct retain cAMP and CRH inducibility at levels similar to the 3500BP-CAT construct. However, deletion of CRH-BP promoter sequences to Ϫ88 bp (88BP-CAT) results in dramatic reductions in both cAMP (Fig. 7, A and B) and CRH inductions (Fig. 7B) . These results suggest that the CRH-BP DNA sequences between Ϫ341 and Ϫ88 bp mediate, in large part, the cAMP and CRH regulation of CRH-BP promoter activity. However, small cAMP and CRH inductions remain in the 88BP-CAT transfections in ␣TSH cells, suggesting that additional sequences may contribute to the cAMP and CRH regulation in these cells.
The identification of potential CREB/ATF and AP-2 transcription factor-binding sites within this region suggested that these CRH-BP DNA sequences might be important for cAMP and/or CRH regulation. The potential cAMP response element (CRE) sequence CGTCA (Ϫ127 to Ϫ123 bp) is a truncated version of the palindromic consensus CRE sequence TGACGTCA, previously shown to be important in the cAMP regulation of many genes (36) . However, the shortened CGTCA motif has been shown to play a role in cAMP regulation of the human GH gene (32) . To determine the role of this potential transcription factorbinding site in CRH-BP promoter regulation, the CGTCA sequence in the CRH-BP 5Ј flanking DNA was mutated to CTCGA using site-directed mutagenesis to create 341(⌬CRE)BP-CAT. This construct is identical to 341BP-CAT, except for the mutation of the putative CRE sequences. When this plasmid is transfected into COS-1 cells, the For/I-mediated induction in CAT activity decreases from 19-fold in 341BP-CAT-transfected cells to 1.2-fold in 
Discussion
To further define the molecular mechanisms regulating CRH-BP gene expression, the rat CRH-BP gene was isolated and characterized. Southern blot analysis of rat genomic DNA with a 187-bp CRH-BP cDNA-specific probe demonstrates a single hybridization-positive fragment with each restriction endonuclease, providing evidence for a single CRH-BP gene in the rat genome. Restriction endonuclease mapping and nucleotide sequence analysis of the isolated rat genomic clones demonstrate that the rat CRH-BP gene contains seven exons and six introns, similar to the human CRH-BP gene. The nucleotide sequences of the proteinencoding exons are highly homologous in the human and rat CRH-BP genes, and all the exon/intron boundaries have been conserved. In addition, the first 215 bp of the 5Ј flanking DNA also are highly homologous (Ͼ85%) between the rat and human genes, suggesting that important transcriptional control elements have been conserved through evolution to maintain the regulation of the CRH-BP gene.
To define a potential rat CRH-BP promoter sequence, transcription initiation sites in the rat CRH-BP gene were identified (Fig. 4) . RNase protection assays revealed that CRH-BP transcripts initiate at multiple sites in rat cerebral cortex, including a major initiation site. The major CRH-BP initiation site in rat cerebral cortex corresponds to the previously mapped human liver CRH-BP CAP site (23) and is located 31 nucleotides 3Ј to a conserved TATA sequence (Ϫ31 to Ϫ25; Fig. 3 ). The identification of multiple upstream initiation sites is consistent with the isolation of rat and mouse brain CRH-BP cDNAs with 5Ј ends that extend beyond the 5Ј end of the human liver CRH-BP cDNA (7, 8) . The number and pattern of transcription initiation sites were similar in rat cerebral cortex and pituitary, indicating that the mechanisms controlling basal CRH-BP gene transcription are similar in these tissues. The DNA sequences controlling transcription initiation at upstream sites may include the TATA sequence at Ϫ221 and Sp1 sites at Ϫ147 and Ϫ169 (37) . The presence of multiple sites of transcription initiation of the CRH-BP gene in rat brain and pituitary, but not in human liver, may be explained partly by the differences in the 5Ј flanking DNA of the rat and human CRH-BP genes. Alternatively, multiple transcription initiation sites also may exist for the CRH-BP gene expressed in human brain and pituitary, suggesting that the different transcription initiation sites may be tissue-specific.
The identification of CRH-BP transcription initiation sites suggested that the 3.5-kb SacI fragment of the rat CRH-BP gene would contain functional promoter activity. Transfection experiments with the 3500BP-LUC construct in cultured mammalian cells demonstrated basal CRH-BP promoter activity in a variety of different cell types, including neuroblastoma (Neuro-2a and NIE-115), anterior pituitary corticotrope (AtT-20), anterior pituitary thyrotrope (␣TSH), adrenal (PC12), and kidney (COS-1) cells. Analysis of deletion mutants of the 3500BP-LUC construct indicates that nucleotides Ϫ341 to ϩ66 of the rat CRH-BP gene contain promoter activity equivalent to nucleotides Ϫ3500 to ϩ66 in Neuro-2a and COS-1 cells. Removal of nucleotides Ϫ341 to Ϫ88, which deletes transcription initiation sites 5Ј of the 160 marker in Fig. 4B , results in decreased promoter activity in COS-1, Neuro-2a, and ␣TSH cells (Fig. 5B) . These results suggest that nucleotide sequences between Ϫ341 to Ϫ88 may play a role in directing basal transcription of the rat CRH-BP gene, in addition to the basal promoter activity contained within nucleotides Ϫ88 to ϩ1.
Several neuronal and neuroendocrine cell lines were selected for transfection experiments because rat CRH-BP mRNA is expressed in brain and pituitary. To determine whether these cell lines express endogenous CRH-BP mRNA, Northern blot analysis was performed with 20 -50 g total RNA. CRH-BP mRNA was not detected in any cell line. However, RT-PCR and RNase protection (with 50 -100 g total RNA) experiments indicate that Neuro-2a, NIE-115, AtT20, and PC12 cells express endogenous CRH-BP mRNA at very low levels. Although CRH-BP mRNA was not detected in COS-1 cells by Northern blot, more sensitive analysis of COS-1 RNA by RT-PCR and RNase protection was not possible because the monkey CRH-BP cDNA has not been isolated. Although CRH-BP mRNA is expressed at very low, basal levels in a variety of neuronal and neuroendocrine cell lines, the tissue-and cell-specific expression of CRH-BP in vivo may require DNA elements not included in the CRH-BP promoter constructs and/or cell-specific transcription factors.
The presence of potential CREB/ATF and AP-2 transcription factor-binding sites in the 5Ј flanking DNA suggested that CRH-BP gene transcription might be regulated by cAMP. This hypothesis was supported by the finding that rat CRH-BP promoter activity from the 3500BP-CAT construct was induced by forskolin or forskolin/IBMX treatment in multiple cell lines. Similar results were observed with the 341BP-CAT construct, whereas the 88BP-CAT construct exhibited dramatically reduced inductions in CRH-BP-CAT activity after forskolin (␣TSH) or forskolin/IBMX (COS-1) treatment. These results indicated that the DNA sequences between nucleotides Ϫ341 to Ϫ88 of the rat CRH-BP promoter, including potential CRE and AP-2 sites, were required for transcriptional regulation by cAMP. Mutation of the putative CRE sequence (CGTCA) at Ϫ127 bp decreased cAMPmediated inductions in COS and ␣TSH cells to the levels observed with the 88BP-CAT construct, demonstrating the important role of the CGTCA sequence in the cAMP regulation of CRH-BP promoter activity. These results suggest that the CREB/ATF family of transcription factors that binds to CRE sequences may be important mediators of the cAMP regulation of CRH-BP promoter activity.
The demonstration of positive cAMP regulation of CRH-BP promoter activity is consistent with a recent study showing positive forskolin/IBMX regulation of steady-state CRH-BP mRNA levels in primary cultured rat neurons and astrocytes (22) . Our results suggest that the induction of steady-state CRH-BP mRNA levels by cAMP in these cells may be mediated, at least in part, by positive regulation of CRH-BP gene transcription.
The demonstration of positive cAMP regulation of CRH-BP promoter activity also raised the possibility that CRH-BP gene transcription might be regulated by CRH, via the G s -coupled CRH receptor, in cells that express both CRH-BP and CRH receptor, such as anterior pituitary corticotropes. AtT-20 cells, which serve as an excellent model for anterior pituitary corticotropes in culture, were transfected with the 3500BP-CAT construct to study the CRH regulation of CRH-BP promoter activity. Although the basal expression of CRH-BP-CAT constructs in these cells is very low because of poor transfection efficiency, treatment of the transfected cells with CRH resulted in increased CRH-BP promoter activity. This result demonstrates that CRH can positively regulate CRH-BP promoter activity in AtT-20 cells via endogenous CRH receptors. To further characterize the regulation by CRH, ␣TSH (anterior pituitary thyrotrope-like) cells were
